Take our Addiction Test

Find a therapist to overcome addiction

Medicare expanded coverage of GLP-1 agonist medications for weight loss and other indications.

While not specifically approved for this purpose, GLP-1 agonists show promise for addiction.

Special considerations include risks of loss of bone density or muscle mass, as well as pancreatitis.

On July 1, 2026, Medicare launched the GLP-1 Bridge Program for Foundayo (orforglipron), Wegovy (semaglutide), and Zepbound (tirzepatide). For the next 18 months, the program flattens the price of these medications, which are commonly prescribed in primary care settings for weight loss, from an upward range of more than $1000 per month to just $50 per month. To be eligible, beneficiaries must have a body mass index (BMI) of at least 35, or 27-30 if they have another qualifying medical condition like diabetes or a history of heart attack or stroke. Nearly 4 million people are expected to meet criteria.

Absent from the list of qualifying conditions is addiction. But evidence for the use of GLP-1 agonist medications to treat substance use disorders is growing. Primary care providers should take note of the benefits as well as risks particular to patients 65 and older.

GLP-1 agonists, addiction, and seniors

The receptors for GLP-1 agonist medications are found in the brain as well as the gastrointestinal tract. In........

© Psychology Today